Abstract
According to a recent World Health Organization survey, there are over four hundred million people worldwide suffering from mental and neurological disorders schizophrenia affects some forty-five million people, and unipolar major depression ranked fifth in major causes of disability and death. Clearly it is of the utmost importance to develop new, effective, and safe neuro-pharmaceuticals with this increasing global burden of disease. To this end, we have developed a strategy of generating monoclonal antibodies that act as modulators of the cell-surface central nervous system receptor-ion channel complexes. In this review we will focus on the generation and characterization of a monoclonal antibody that acts as a partial agonist to the N-methyl-D-aspartate receptor. The creation of peptide mimetics, derived from this monoclonal antibody, that may be useful as cognitive enhancers and protect neurons hypoxic and ischemic insults caused by stroke, will also be discussed.
Keywords: methyl-D-Aspartate Receptors, anticonvulsant MK-801, Monoclonal Antibody Production, Primary Hippocampal Cultures, TCP Binding Assays, B6B21, Peptide Synthesis
Current Drug Targets
Title: The Use of Antibody Engineering to Create Novel Drugs that Target N-methyl-D-Aspartate Receptors
Volume: 2 Issue: 3
Author(s): Joseph R. Moskal, Hirotaka Yamamoto and Patricia A. Colley
Affiliation:
Keywords: methyl-D-Aspartate Receptors, anticonvulsant MK-801, Monoclonal Antibody Production, Primary Hippocampal Cultures, TCP Binding Assays, B6B21, Peptide Synthesis
Abstract: According to a recent World Health Organization survey, there are over four hundred million people worldwide suffering from mental and neurological disorders schizophrenia affects some forty-five million people, and unipolar major depression ranked fifth in major causes of disability and death. Clearly it is of the utmost importance to develop new, effective, and safe neuro-pharmaceuticals with this increasing global burden of disease. To this end, we have developed a strategy of generating monoclonal antibodies that act as modulators of the cell-surface central nervous system receptor-ion channel complexes. In this review we will focus on the generation and characterization of a monoclonal antibody that acts as a partial agonist to the N-methyl-D-aspartate receptor. The creation of peptide mimetics, derived from this monoclonal antibody, that may be useful as cognitive enhancers and protect neurons hypoxic and ischemic insults caused by stroke, will also be discussed.
Export Options
About this article
Cite this article as:
Moskal R. Joseph, Yamamoto Hirotaka and Colley A. Patricia, The Use of Antibody Engineering to Create Novel Drugs that Target N-methyl-D-Aspartate Receptors, Current Drug Targets 2001; 2 (3) . https://dx.doi.org/10.2174/1389450013348399
DOI https://dx.doi.org/10.2174/1389450013348399 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Enigmatic Drug Binding Site for Sodium Channel Inhibitors
Current Molecular Pharmacology Inflammation and Neurogenesis in Temporal Lobe Epilepsy
Current Drug Targets - CNS & Neurological Disorders Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Therapeutic Potential of Natural Products from Terrestrial Plants as TNF-α Antagonist
Current Topics in Medicinal Chemistry Effects of Static Magnetic Fields on Blood Pressure in Animals and Humans
Current Hypertension Reviews What is the Role of Lithium in Epilepsy?
Current Neuropharmacology Peptidyl Arginine Deiminases and Neurodegenerative Diseases
Current Medicinal Chemistry SPECT Radiopharmaceuticals for Dementia
Current Radiopharmaceuticals Action Mechanisms of Chinese Herbal Compound at the Molecular Level
Letters in Drug Design & Discovery Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry Scientific Basis for the Use of Indian Ayurvedic Medicinal Plants in the Treatment of Neurodegenerative Disorders: 1. Ashwagandha
Central Nervous System Agents in Medicinal Chemistry Editorial [Hot Topic: Ion Channels as a Target for Drug Design )Executive Editor: Kwok-Keung Tai)]
Current Pharmaceutical Design Calcium Channel α2δ Subunits: Structure, Functions and Target Site for Drugs
Current Neuropharmacology Editorial [Hot Topic: Drugs and Pregnancy (Guest Editor: Zaneta Kimber-Trojnar)]
Current Pharmaceutical Biotechnology Influence of CYP3A5 Polymorphism on the Pharmacokinetics of Psychiatric Drugs
Current Drug Metabolism Potential Therapeutic Role of Carnitine and Acetylcarnitine in Neurological Disorders
Current Pharmaceutical Design Nuezhenide Exerts Anti-Inflammatory Activity through the NF-κB Pathway
Current Molecular Pharmacology Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies
Current Medicinal Chemistry Oxidative Stress, Mitochondrial Dysfunction, and Stress Signaling in Alzheimers Disease
Current Alzheimer Research Ultra-Performance Liquid Chromatography Coupled with a Triple Quadrupole Mass Spectrometric Method for the Quantification of Antiepileptic Drugs Methsuximide and Normesuximide in Human Plasma and its Application in a Pharmacokinetic Study
Current Pharmaceutical Analysis